LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated lung cancer in first-line

LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated lung cancer in first-line

EMJ

4 years
468 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD, from Dana-Farber Cancer Institute, Boston, MA, discusses the results to date of LUX-Lung 7, a global, randomised, open-label, phase 2b clinical trial comparing afatinib, an irreversible ErbB family blocker, to gefitinib for the first-line treatment of patients who have epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay